



Tfed
\$

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/719,662
Filing Date	November 21, 2003
First Named Inventor	Sonia Vadrucci
Art Unit	1635
Examiner Name	Richard A. Schnizer
Attorney Docket Number	58572-002

ENCLOSURES <i>(Check all that apply)</i>		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): -42 references -return receipt postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	PROSKAUER ROSE LLP		
Signature			
Printed name	Rebekka C. Noll		
Date	January 22, 2007	Reg. No.	46,962

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Rebekka C. Noll	Date	January 22, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Application No. 10/719,662
Attorney Docket No. 58572-002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Sonia Vadrucci et al.

Application No.: 10/719,662

Filed: November 21, 2003

For: HIGH-EFFICIENCY FUSOGENIC
VESICLES, METHODS OF PRODUCING
THEM, AND PHARMACEUTICAL
COMPOSITIONS CONTAINING THEM

Group Art Unit: 1635

Examiner: Richard A. Schnizer

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR §§1.97 and 1.98, the items identified in this Information Disclosure Statement (“IDS”) are brought to the attention of the Office. The items are listed on the attached form PTO/SB/08a.

The items identified in this IDS may or may not be “material” pursuant to 37 CFR §1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR §1.97(h)), or even qualifies as “prior art” under 35 USC § 102 with respect to this invention unless specifically indicated. 01 FC:1886 10719662
such.

01 FC:1886 10719662
100.00 DA

Information Disclosure Statement Filing Provision:

- This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.
- However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) to the deposit account referenced below.
- However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.
- This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.
- The fee due under 37 CFR § 1.17(p) is submitted herewith.
- A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.
- This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

Statement Under 37 CFR §1.97(e):


- Each item contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
- No item contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this IDS.

Payment and/or Authorization to Charge Fees:

- A check in the amount of _____ is enclosed for the above fee(s).
- Please charge \$180.00 to Deposit Account No.16-2500 for the above fee(s).

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Proskauer Rose LLP's Deposit Account No.16-2500.


Respectfully submitted,
PROSKAUER ROSE LLP
Attorneys for the Applicant(s)

By 
Rebekka C. Noll
Reg. No. 46,962

January 22, 2007

PROSKAUER ROSE LLP
1585 Broadway
New York, NY 10036-8299
Tel: (212) 969-3000

Attachment: PTO/SB/08a & b



PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Substitute for form 1449/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/719,662
		Filing Date	November 21, 2003
		First Named Inventor	Sonia Vadrucci
		Art Unit	1635
		Examiner Name	Richard A. Schnizer
Sheet	1	of	5
		Attorney Docket Number	

Sheet 1

5

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		WO 98/52603 A	11-26-1998			
		WO 2004/045582 A1	06-03-2004			
		PCT/EP03/12955	03/29/2004	Int'l Search Report		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes at USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/719,662
				Filing Date	November 21, 2003
				First Named Inventor	Sonia Vadrucci
				Art Unit	1635
				Examiner Name	Richard A. Schnizer
Sheet	2	of	5	Attorney Docket Number	58572-002

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		HARTER, ET. AL., Hydrophobic Binding of the Ectodomain of Influenza Hemagglutinin to Membranes Occurs through..... 4/15/, Vol 264, No 11, pp.6459-6464,1989, Zurich Switzerland			
		ERIC H. BALL, Quantitation of Proteins by Elution of Coomassie Brilliant Blue R from Stained Bands after Sodium Dodecyl....., 7/29/85, 155, 23-27 (1986) Canada			
		E. BEUTLER ET. AL., The removal of leukocytes and platelets from whole blood , 8/15/75, volume 88, number 2, Freiburg, Germany			
		ROMKE BRON ET AL., Preparation, Properties, and Applications of Reconstituted Influenza virus Envelopes (Virosomes), 1993, pgs. 313-331, Vol. 220 Academic Press, Inc.			
		ROMKE BRON ET. AL., Cellular Cytoplasmic Delivery of a Polypeptide Toxin by Reconstituted Influenza virus Envelopes..... 1994, pgs. 9110-9117, vol 33,American Chemical Society			
		JEAN-YVES, Delivery of Plasmid DNA into Mammalian Cell Lines using pH-Sensitive Liposomes, 1/27/92, vol. 9, No. 0, 1992, Plenum Publishing Corp.,			
		S.U. EGELHAAF, ET AL., New controlled vitrification system for cryo-transmission....., 4/7/2000, Journal of Microscopy, Vol. 200, Pt2, Nov. 2000 pp. 128-139, Switzerland			
		WALTER CERHARD, The Analysis of the Monoclonal Immune Response to Influenza Virus, 1976, Vol. 144 pg. 985-995, The Journal of Experimental Medicine, Pennsylvania			
		HEZI GERSHON ET AL., Mode of Formation and Structural Features of DNA-Cationic Liposome....., 1993, 32,pgs. 7143-7151, The Weizmann Institute of Science, Israel			
		REINHARD GLUCK,Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs),1999, pgs.1782-1787, Swiss Serum & Vaccine Institute Berne CH-3001 Switzerland			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/719,662	
		Filing Date	November 21, 2003	
		First Named Inventor	Sonia Vadrucci	
		Art Unit	1635	
		Examiner Name	Richard A. Schnizer	
Sheet	3	of	5	Attorney Docket Number
58572-002				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		J. MOL. Biol, Selective Extraction of Polyoma DNA from Infected Mouse Cell Cultures, 1967, 26, pgs. 365-369	
		ENRICO MASTROBATTISTA ET AL., Targeting influenza virosomes to ovarian carcinoma cells, 3 July 2001, pgs. 71-76, Utrecht Institute for Pharmaceutical Sciences.	
		PIERRE-ALAIN MONNARD, ET AL. Entrapment of nucleic acids in liposomes, February 24, 1997, pgs 39-50, Zurich Switzerland	
		ISABEL NUNES-CORREIA ET AL., Interactions of Influenza virus with Cultured Cells: Detailed Kinetic Modeling of Binding.....,1999, pgs. 1095-1101, American Chemical Society	
		THOMAS OBERHOLZER, ET. AL. Enzymatic reactions in liposomes using th detergent-induced liposome loading method, 1999, pgs. 57-68, Zurich Switzerland	
		HERMANN SCHAGGER ET. AL., Tricine-Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis for the Separation of Proteins in the Range from.....,1987, pgs.368-379, Germany	
		PIETER SCHOEN, ET AL., Delivery of Foreign Substances to Cells Mediated By Fusion-Active Reconstituted.....,1993, pgs. 767-792, Journal of Liposome Research, The Netherlands	
		TAKEHIRO SERIKAWA, ET.AL., A new cationic liposome for efficient gene delivery with serum into cultured....., 2000 pgs. 419-430, Dept. of Biochemistry and Cell Biology, Japan	
		TONG SHANGGUAN ET AL., Influenza Virus-Liposome Lipid Mixing is Leaky and Largely Insensitive....., 1996, pgs. 4956-4965, Dept. of Bioscience and Biotechnology, Pennsylvania	
		JOHN J. SKEHEL, ET. AL., The Polypeptide Composition of Influenza A Viruses, 1971, pgs. 396-408, National Institute for Medical Research, Mill Hill, London N.W. 7. England	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/719,662
Sheet	4	of	5	Filing Date	November 21, 2003
				First Named Inventor	Sonia Vadrucci
				Art Unit	1635
				Examiner Name	Richard A. Schnizer
				Attorney Docket Number	58572-002

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		THEODORE L. STECK ET. AL., Preparation of Impermeable Ghosts and Inside-out Vesicles from Human Erythrocyte Membranes, 1970, pgs. 172-181,		
		TOON STEGMANN, Membrane Fusion Mechanisms: The Influenza Hemagglutinin Paradigm and its Implications for....., 2000 pgs. 598-604, Munksguard International Publishers		
		DOUGLAS K. STRUCK ET. AL., Use of Resonance Energy Transfer To Monitor Membrane Fusion, 1981, pgs. 4093-4099, American Chemical Society		
		MASATO TSURUDOME ET. AL., Lipid Interactions of the Hemagglutinin HA2 NH2-terminal Segment....., 1992, Vol. 267 No. 28 pgs. 20225-20232, The Journal of Biological Chemistry		
		ANDREAS WAGNER, ET.AL., Enhanced Protein Loading Into Liposomes by the Multiple Crossflow Injection Technique, 2002, Vol. 12, No. 3 pp. 271-283, Journal of Liposome Research		
		JOSEPH ZABNER, Cellular and Molecular Barriers to Gene Transfer by a Cationic Lipid, The Journal of Biological Chemistry, 1995 pgs.18997-19007 Vol. 270, No. 32, Iowa City, Iowa		
		RINALDO ZURBRIGGEN, ET.AL., IRIV-adjuvanted hepatitis A Vaccine: in vivo absorption and biophysical characterization, 2000, Progress in Lipid Research 39 pgs. 3-18 Switzerland		
		PETER DURRER, ET. AL., H+induced Membrane Insertion of Influenza Virus....., The Journal of Biological Chemistry, 1996, vol. 271. No. 23 pgs. 13417-1342, Basel, Switzerland		
		THOMAS KORTE, ET. AL., Transient Changes of the Conformation of Hemagglutinin of...,Journal of Biological Chemistry Vol. 272, No. 15, pgs. 9764-9770,1997, Berlin Germany		
		THOMAS KORTE, ET. AL., Conformational Intermediates and Fusion Activity of, Journal of Virology, June 1999, Vol. 73 No. 6 p. 4567-4574, Bethesda, Maryland		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/719,662
				Filing Date	November 21, 2003
				First Named Inventor	Sonia Vadrucci
				Art Unit	1635
				Examiner Name	Richard A. Schnizer
Sheet	5	of	5	Attorney Docket Number	58572-002

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		MICHAEL M. KOZLOV, ET. AL., A Mechanism of Protein-Mediated Fusion: Coupling between Refolding of....., Biophysical Journal Vol. 75 1998 pgs. 1384-1396, Bethesda, Maryland			
		ANU PURI, ET.AL., Conformational Changes and Fusion Activity of Influenza Virus Hemagglutinin....., Journal of Virology, 1990 Vol. 64, No. 8, pgs. 3824-3832, San Francisco, CA			
		HUI QIAO, ET.AL., Specific Single or Double Proline Substitutions in the.....The Journal of Cell Biology, Vol. 141, No. 6, 1998, pgs. 1335-1347, San Francisco, CA			
		TOON STEGMANN, ET.AL., Effects of Low pH on Influenza Virus, The Journal of Biological Chemistry, 1987, vol. 262, No. 36, pgs. 17744-17749, The Netherlands			
		TOON STEGMANN, ET.AL., The HA2 Subunit of Influenza Hemagglutinin Inserts into...., the Journal of Biological Chemistry, Vol. 266, No. 27, 1991, pg. 18404-18410, New Haven, CT			
		TOON STEGMANN, ET.AL., Functional reconstitution of influenza virus envelopes, The EMBO Journal vol. 6 no. 9 pgs. 2651-2659, 1987, The Netherlands			
		TOON STEGMANN, ET.AL., Intermediates in influenza induced membran fusion, The EMBO Journal vol.9 no.13 pgs. 4231-4241, 1990, San Francisco, CA			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.